Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 79, Issue 6, Pages 1221-1227Publisher
SPRINGER
DOI: 10.1007/s00280-017-3322-9
Keywords
Cilengitide; Av beta 3 and alpha v beta 5 integrins; Paclitaxel; Solid tumors
Categories
Funding
- NIH Grant [K12 CA90628]
- CTSA Grant from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH [UL1 TR000135]
- NCI
Ask authors/readers for more resources
Purpose Cilengitide is a potent and selective inhibitor of the integrins alpha v beta 3 and alpha v beta 5. The primary objective of this phase I clinical trial was to establish the maximum tolerated dose and determine safety/tolerability of cilengitide in combination with paclitaxel in patients with advanced solid tumors. Secondary objectives included the evaluation of the preliminary clinical outcomes. Patients and methods Patients with advanced solid tumors experiencing disease progression on standard treatment were assigned to two different dose levels of cilengitide (2000 mg intravenously once or twice weekly) in combination with fixed-dose, weekly paclitaxel (90 mg/m(2) intravenously). Results Twelve evaluable patients were treated per protocol. A single dose limiting toxicity (DLT) of grade 4 neutropenia was observed at the starting dose level of once weekly cilengitide. There were no grade >= 3 adverse events that occurred with >10% frequency. One patient achieved a partial response to therapy. Five patients experienced stable disease as best response, 3 of which discontinued study participation due to progressive, peripheral neuropathy. Conclusions Cilengitide in combination with paclitaxel was well tolerated. Antitumor activity was observed. The recommended phase II dose is twice weekly cilengitide (2000 mg) with weekly paclitaxel (90 mg/m(2)). Further studies evaluating drugs that target this pathway are warranted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available